Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 5
2014 4
2015 5
2016 4
2017 4
2018 5
2019 6
2020 6
2021 8
2022 12
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bai cong xia (1 results)?
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Multi-omics characterization of silent and productive HPV integration in cervical cancer.
Fan J, Fu Y, Peng W, Li X, Shen Y, Guo E, Lu F, Zhou S, Liu S, Yang B, Qin X, Hu D, Xiao R, Li X, Yang S, Yuan C, Shu Y, Huang H, Wan T, Pi Y, Wang S, Chen W, Wang H, Zhong L, Yuan L, Wen B, Kong B, Mills GB, Zou D, Xia B, Song K, Chen G, Ma D, Sun C. Fan J, et al. Among authors: xia b. Cell Genom. 2023 Jan 11;3(1):100211. doi: 10.1016/j.xgen.2022.100211. eCollection 2023 Jan 11. Cell Genom. 2023. PMID: 36777180 Free PMC article.
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.
Li K, Chen J, Hu Y, Wang YZ, Shen Y, Chen G, Peng W, Fang Z, Xia B, Chen X, Song K, Wang Y, Zou D, Wang YC, Han Y, Feng X, Yuan J, Guo S, Meng X, Feng C, Chen Y, Yang J, Fan J, Wang J, Ai J, Ma D, Sun C. Li K, et al. Among authors: xia b. Lancet Oncol. 2024 Jan;25(1):76-85. doi: 10.1016/S1470-2045(23)00531-4. Epub 2023 Dec 1. Lancet Oncol. 2024. PMID: 38048802 Clinical Trial.
Therapeutic applications of PARP inhibitors in ovarian cancer.
Xie H, Wang W, Xia B, Jin W, Lou G. Xie H, et al. Among authors: xia b. Biomed Pharmacother. 2020 Jul;127:110204. doi: 10.1016/j.biopha.2020.110204. Epub 2020 May 15. Biomed Pharmacother. 2020. PMID: 32422564 Free article. Review.
Mesonephric-like adenocarcinoma of the ovary.
Yang Y, Zhao M, Jia Q, Tang H, Xing T, Li Y, Tang B, Xu L, Wei W, Zheng H, Shi R, Xia B, Chen J. Yang Y, et al. Among authors: xia b. J Ovarian Res. 2024 Mar 5;17(1):57. doi: 10.1186/s13048-024-01383-7. J Ovarian Res. 2024. PMID: 38444000 Free PMC article.
67 results